Qatar Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Qatar Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Qatar Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Qatar's pharmaceuticals and healthcare sectors will continue to grow despite challenges facing the government's revenue streams. Both an increase in public spending on health, including in infrastructure projects, and the rising participation of the private sector in healthcare funding will sustain robust sector growth over the forecast period . In fact, w hile Qatar will likely remain on track with its development objectives to become a major healthcare player in the region , the rising demand for healthcare, which is in part driven by the growing prevalence of chronic diseases, will support renewed opportunities for drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.91bn (USD524mn) in 2015 to QAR2.04bn (USD559mn) in 2016; +6.8% in local currency and US dollar terms. Forecast unchang ed from last quarter .

  • Healthcare: QAR18.49bn (USD5.08bn) in 2015 to QAR19.85bn (USD5.45bn) in 2016; +7.3% in both local currency and US dollar terms. Forecast revised slightly downwards from last quarter .

Headline Pharmaceuticals & Healthcare Forecasts (Qatar 2014-2020)
2014 2015e 2016f 2017f 2018f 2019f 2020f
e/f = BMI estimate/forecast. Source: World Health Organization (WHO), BMI
Pharmaceutical sales, USDbn 0.491 0.524 0.559 0.596 0.634 0.673 0.714
Pharmaceutical sales, % of GDP 0.23 0.28 0.27 0.26 0.26 0.25 0.24
Pharmaceutical sales, % of health expenditure 10.4 10.3 10.3 10.2 10.1 9.9 9.8
Health spending, USDbn 4.737 5.079 5.451 5.856 6.294 6.768 7.282

Risk/Reward Index

In Q216, we have revised downwards Qatar's Risk/Reward Index score to 53.6 from 55.5 previously (out of 100). Qatar's score revision was mainly driven by lower industry and country rewards indices. Qatar shifted down one ranking position to fifth out of 31 markets in the Middle East and Africa region in terms of attractiveness to pharmaceutical investors. Qatar's score is driven by high spending per capita on medicine and high sector value growth, but is dragged down by a small market size and a small pensionable population.

Latest Updates

  • Despite cutbacks to other sectors in the Qatari government's 2016 budget, healthcare spending is set to rise to QAR16.4bn (USD4.5bn) in the same year, up from QAR15.5bn (USD4.2bn) in 2015, while several healthcare capital projects have been highlighted by the government, such as increased funding to the Sidra Medical and Research Center, the set up of five new health centres and a cancer treatment centre, and the completion of Hamad General Hospital and Hamad Medical City.

  • According to Qatar's Supreme Council of Health annual report, 11 new hospitals and medical research facilities are anticipated to be established in the country by 2022, including the USD635mn Hamad Bin Khalifa Medical City.

  • Against this background, and rising healthcare spending figures, the Supreme Council of Health confirmed that Qatar's National Health Strategy 2011-2016 is on track to achieve the health objectives set in the National Vision 2030, which confirms Qatar's increased focus on healthcare and in achieving its aim of becoming a major healthcare player in the region.

  • In December 2015, Qatar's Supreme Council of Health announced that the National Health Insurance (Seha) will be phased out through H116 and substituted by coverage provided by private insurers, with tenders for private insurance companies starting in February 2016 and the new system operational by June 2016.

  • Qatar's new National Health Strategy 2017-2022 is expected to be announced in June 2016 and will focus on providing healthcare through the private insurance system to the country's large population of blue-collar expats, including more free medical testing, health education and medicines to this population segment over the coming years (Doha News).

BMI Economic View

The performance of the Qatari economy will be more mixed than in recent years, amid the intertwined pressures of the global energy slump and tightening domestic liquidity. We forecast real economic growth of 5.0% this year and 4.8% in 2017, driven mainly by strong growth in the primary and secondary sectors.

BMI Political View

A shift in Qatar's foreign policy, the erosion of vested interests at home, and the sidelining of older political figures - combined with the long-running internal rivalries of the al-Thani family - could in theory threaten Qatari Emir Tamim bin Hamad al-Thani's grip on power. However, Tamim has successfully consolidated his power, and we do not view his removal as likely.

BMI Industry View
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Qatar 2011-2019)
12
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2011-2019)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2011-2019)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2011-2019)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
21
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
23
OTC Market Forecast
24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
25
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (Qatar 2013-2019)
27
Table: Pharmaceutical Trade Data And Forecasts local currency (Qatar 2013-2019)
28
Key Risks To BMI's Forecast Scenario
29
Industry Risk/Reward Index
32
Middle East and Africa Risk/Reward Index - Q1 2016
32
Qatar Risk/Reward Index
40
Reward
40
Risk
41
Regulatory Review
42
Regional Regulatory Developments
43
Intellectual Property Regime
46
Pricing And Reimbursement Regime
46
Market Overview
49
Healthcare Sector
50
GCC Unified Drug Pricing
54
Table: Healthcare Resources (Qatar 2009-2014)
56
Table: Healthcare Personnel (Qatar 2009-2014)
56
Table: Healthcare Activity (Qatar 2009-2014)
56
Health Insurance
57
Healthcare IT
60
Research & Development
60
Clinical Trials
62
Epidemiology
63
Competitive Landscape
67
Pharmaceutical Industry
67
Pharmaceutical Wholesale And Retail
69
Table: Multinational Company Activity
69
Company Profile
71
Ebn Sina Medical
71
Medicare Group
73
Qatar Pharma
75
Demographic Forecast
77
Table: Population Headline Indicators (Qatar 1990-2025)
79
Table: Key Population Ratios (Qatar 1990-2025)
79
Table: Urban/Rural Population & Life Expectancy (Qatar 1990-2025)
80
Table: Population By Age Group (Qatar 1990-2025)
80
Table: Population By Age Group % (Qatar 1990-2025)
81
Glossary
82
Methodology
84
Pharmaceutical Expenditure Forecast Model
84
Healthcare Expenditure Forecast Model
84
Notes On Methodology
85
Risk/Reward Index Methodology
86
Index Overview
87
Table: Pharmaceutical Risk/Reward Index Indicators
87
Indicator Weightings
88

The Qatar Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatar pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Qatar, to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.